|
|
GDQ |
|
Vaxjo ID |
477 |
|
Vaccine Adjuvant Name |
GDQ |
|
Adjuvant VO ID |
VO_0005754
|
|
Description |
synthetic imidazoquinoline analog that is a TLR7 agonist and induces a Th1-biased response |
|
Stage of Development |
Research |
|
Location Licensed |
United States |
|
Host Species for Testing |
Mouse |
|
Components |
gardiquimod, an imidazoquinoline analog |
|
Function |
Type: TLR agonist vaccine adjuvant. Target Receptor: Toll-like receptor 7 (TLR7). Induces Th1-biased immune profile. TLR7 acivation which induces IFN-? expression, an antiviral cytokine, and perhaps other antiviral compounds, and by inhibits reverse transcriptase activity |
| References |
Balam et al., 2016: Balam S, Jafarshad A, Servis C, Frank G, Reed S, Pink R, Druilhe P, Spertini F, Corradin G. Immunogenicity of dimorphic and C-terminal fragments of Plasmodium falciparum MSP2 formulated with different adjuvants in mice. Vaccine. 2016; 34(13); 1566-1574. [PubMed: 26874325].
Buitendijk et al., 2013: Buitendijk M, Eszterhas SK, Howell AL. Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells. AIDS research and human retroviruses. 2013; 29(6); 907-918. [PubMed: 23316755].
|
|
